With the development and regulatory approval of immune checkpoint inhibitors and adoptive
cell therapies, cancer immunotherapy has undergone a profound transformation over the …

Major histocompatibility complex (MHC) molecules are expressed on the cell surface, where
they present peptides to T cells, which gives them a key role in the development of T-cell …

The immunopeptidome is the repertoire of peptides bound and presented by the MHC class
I, class II, and non-classical molecules. The peptides are produced by the degradation of …

Major histocompatibility complex II (MHC II) molecules play a vital role in the onset and
control of cellular immunity. In a highly selective process, MHC II presents peptides derived …

Predictions of epitopes presented by class II human leukocyte antigen molecules (HLA-II)
have limited accuracy, restricting vaccine and therapy design. Here we combined unbiased …

CD4+ T cells orchestrate the adaptive immune response against pathogens and cancer by
recognizing epitopes presented on class II major histocompatibility complex (MHC-II) …

The new food-derived bio-functional peptides are urgently needed globally, but the
separation and purification process for obtaining the immunopeptides from food is low …

The success of antibody therapeutics is strongly influenced by their multifunctional nature
that couples antigen recognition mediated by their variable regions with effector functions …

T cell cancer neoantigens are created from peptides derived from cancer-specific aberrant
proteins, such as mutated and fusion proteins, presented in complex with human leukocyte …

Introduction: Cancer neoantigens represent important targets of cancer immunotherapy. The
goal of cancer neoantigen vaccines is to induce neoantigen-specific immune responses and …